DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
DREAMM-2: Indirect Comparisons of Belantamab Mafodotin vs. Selinexor + Dexamethasone and Standard of Care Treatments in Relapsed/Refractory Multiple Myeloma
Authors
Keywords
-
Journal
ADVANCES IN THERAPY
Volume 38, Issue 11, Pages 5501-5518
Publisher
Springer Science and Business Media LLC
Online
2021-09-25
DOI
10.1007/s12325-021-01884-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Selinexor for the treatment of multiple myeloma
- (2020) Klaus Podar et al. EXPERT OPINION ON PHARMACOTHERAPY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma
- (2019) Ajai Chari et al. NEW ENGLAND JOURNAL OF MEDICINE
- Assessment-Schedule Matching in Unanchored Indirect Treatment Comparisons of Progression-Free Survival in Cancer Studies
- (2019) Venediktos Kapetanakis et al. PHARMACOECONOMICS
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies
- (2019) Luciano J. Costa et al. BLOOD
- Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study
- (2019) Sagar Lonial et al. LANCET ONCOLOGY
- Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
- (2018) Dan T. Vogl et al. JOURNAL OF CLINICAL ONCOLOGY
- Drug resistance in multiple myeloma
- (2018) Pawel Robak et al. CANCER TREATMENT REVIEWS
- Multiple myeloma: patient outcomes in real-world practice
- (2016) Kwee Yong et al. BRITISH JOURNAL OF HAEMATOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Multiple Myeloma: Diagnosis and Treatment
- (2016) S. Vincent Rajkumar et al. MAYO CLINIC PROCEEDINGS
- Multiple myeloma epidemiology and survival: A unique malignancy
- (2016) Dickran Kazandjian SEMINARS IN ONCOLOGY
- Prevalence of hypercalcemia among cancer patients in the United States
- (2016) Victor M. Gastanaga et al. Cancer Medicine
- Targeting B-cell maturation antigen in multiple myeloma
- (2015) Yu-Tzu Tai et al. Immunotherapy
- Ocular Adverse Events Associated with Antibody–Drug Conjugates in Human Clinical Trials
- (2015) Joshua Seth Eaton et al. JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started